Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Amgen
Fierce Pharma
FDA's response letter salvo sheds light on drug refusal process
The FDA's response letter salvo offers an in-depth view into the high-stakes discussions that decide whether a medicine will ever make it to market.
James Waldron
,
Fraiser Kansteiner
Jul 11, 2025 10:15am
Amgen, Zai say stomach cancer candidate hits phase 3 mark
Jun 30, 2025 10:36am
Amgen's ph. 3 MariTide studies will ramp up dosing to quell nausea
Jun 24, 2025 9:59am
FDA lifts hold on Amgen's phase 1 obesity study
May 2, 2025 10:10am
Lilly links lepodisiran to durably lower lipoprotein in phase 2
Mar 31, 2025 4:24am
Amgen ignites Rocket program with wins in phase 3 eczema trials
Mar 10, 2025 5:48am